CD274 and non-small cell lung carcinoma: Patients with PD-L1+ metastatic NSCLC with progression after at least one prior ICI were randomized to receive acasunlimab monotherapy (arm A), acasunlimab with pembrolizumab 200 mg every 3 weeks (arm B), or acasunlimab with pembrolizumab every 6 weeks (arm C) [34].